Overview
INJ and DRV rarely move in perfect sync. Today’s print ($5.13/$0.098534) and 24h leaders (Injective) help frame which side currently carries relative strength.
Quick winners
Full comparison
| Metric | INJ | DRV |
|---|---|---|
| Price | $5.13 | $0.098534 |
| Market Cap | $513.38M | $98.51M |
| FDV | — | — |
| Volume 24h | $33.36M | $1.72M |
| Circulating Supply | — | — |
| Total Supply | — | — |
| Max Supply | — | — |
| Rank | 98.00 | 259.00 |
| Dominance | — | — |
| Liquidity | — | — |
| Volatility | +5.97% | +3.64% |
| ATH | — | — |
| ATL | — | — |
| ROI | — | — |
Performance
| Timeframe | INJ | DRV |
|---|---|---|
| 1H | — | — |
| 24H | +6.10% | -7.50% |
| 7D | — | — |
| 30D | — | — |
| 90D | — | — |
| 1Y | — | — |
| YTD | — | — |
| ALL | — | — |
Comparative chart
Technical indicators
| Indicator | INJ | DRV |
|---|---|---|
| RSI | 49.29 | 49.02 |
| MACD histogram | — | — |
| EMA20 | — | — |
| EMA50 | — | — |
| EMA100 | — | — |
| EMA200 | — | — |
| SMA50 | — | — |
| SMA200 | — | — |
| ATR | 0.29 | 67.35 |
| ADX | 12.19 | 21.33 |
| Support | 4.91 | 1,827.82 |
| Resistance | 5.47 | 1,960.30 |
| Trend | neutral | bearish |
| Momentum | — | 63.00 |
| Signal | neutral | neutral |
Automatic technical analysis
Technically, Injective shows RSI 49.29 with trend bias neutral, while Derive sits at RSI 49.02 (bearish). Divergences between momentum and price should be confirmed on higher timeframes.
Fundamentals
| Metric | INJ | DRV |
|---|---|---|
| Consensus | — | — |
| Blockchain | — | — |
| TPS | — | — |
| Block time | — | — |
| Finality | — | — |
| Validators | — | — |
| Staking | — | — |
| TVL | — | — |
| Supply model | — | — |
| Inflation | — | — |
| Developer activity | 0.00 | — |
| Github activity | 118.00 | — |
| On-chain activity | — | — |
| Whale activity | — | — |
| Addresses | — | — |
| Gas fees | — | — |
Ecosystem
Injective
Derive
Pros and cons
Pros of Injective
- Composite PEPS readings for Injective can surface clearer module agreement during trend phases.
- INJ often anchors narratives that attract sustained media and analyst coverage.
- Injective has an established coin page footprint on PEPS for continuous monitoring.
Cons of Injective
- When dominance narratives fade, Injective can lag hotter rotation names.
- Indicator stacks on Injective may stay stretched longer than expected in strong trends.
- Large-cap status for Injective can mean slower percentage upside versus high-beta alternatives.
Pros of Derive
- Diversifying versus Injective with Derive can change portfolio factor exposure.
- Active volume bursts on DRV sometimes precede sharper tactical moves.
- If technical momentum aligns, Derive may outperform on medium-term windows.
Cons of Derive
- Trend failures on Derive often travel faster than on more established assets.
- Weaker market-cap standing may leave Derive more exposed to liquidity droughts.
- Incomplete fundamental coverage can hide operational or tokenomic risks.
- Smaller book depth versus large caps can increase slippage for Derive.
Which looks stronger right now?
On the latest snapshot, market-cap leadership belongs to Injective, while short-term performance leans toward Injective. That mix suggests relative strength can flip quickly, so size risk accordingly.
AI summary
This AI-assisted summary starts from live PEPS fields. Injective holds market-cap $513.38M and rank #98; Derive shows $98.51M and #259. Where liquidity and flow matter, watch Injective. Where durability matters, watch Injective. AI composite scores (47.50/58.40) compress those tensions into a single lens. In probabilistic terms, the side winning more columns may have a nearer-term edge, but tails remain fat. Revisit after the next hourly refresh.
FAQ
Which is better, Injective or Derive?
“Better” depends on horizon and risk. Injective leads on market cap today, while Injective leads the 24h move — neither is a guarantee.
Which has more upside potential, INJ or DRV?
Higher-beta assets can move more in both directions. Use performance tables and volatility, not headlines, to judge potential ranges.
Which is less risky right now?
Lower volatility and deeper liquidity usually imply milder path risk, but crypto tails remain large for both Injective and Derive.
Which has stronger developer activity?
Check the fundamentals table for developer/github fields when populated. Missing values mean the feed has no reliable reading yet.
Which looks more decentralized?
Decentralization is multi-dimensional (validators, client diversity, token distribution). This page surfaces available consensus/validator fields without over-claiming.
Which has lower fees?
Fee comparisons belong to each network’s fee market. Where gas/fee metrics exist in fundamentals, compare them; otherwise verify on explorers.
Which is better for investing?
Investing choices need personal constraints. Use this comparison as research input, then size positions with an explicit invalidation plan.
Which is better for staking?
If staking fields are present, compare yield mechanics and lockups off-platform. Staking returns are not risk-free.
Which is more used day to day?
Volume, on-chain activity and ecosystem links are practical usage proxies. Injective currently leads traded volume on this snapshot.
Which has the better recent performance?
See the performance table across 1h through 1y. The 24h leader is Injective, but longer windows can disagree.